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Abstract
Background: To evaluate the performance of a broad scope model-based optimisation process for volumetric
modulated arc therapy applied to esophageal cancer.
Methods and materials: A set of 70 previously treated patients in two different institutions, were selected to train
a model for the prediction of dose-volume constraints. The model was built with a broad-scope purpose, aiming to
be effective for different dose prescriptions and tumour localisations. It was validated on three groups of patients
from the same institution and from another clinic not providing patients for the training phase. Comparison of the
automated plans was done against reference cases given by the clinically accepted plans.
Results: Quantitative improvements (statistically significant for the majority of the analysed dose-volume parameters)
were observed between the benchmark and the test plans. Of 624 dose-volume objectives assessed for plan
evaluation, in 21 cases (3.3 %) the reference plans failed to respect the constraints while the model-based plans
succeeded. Only in 3 cases (<0.5 %) the reference plans passed the criteria while the model-based failed. In 5.3 % of
the cases both groups of plans failed and in the remaining cases both passed the tests.
Conclusions: Plans were optimised using a broad scope knowledge-based model to determine the dose-volume
constraints. The results showed dosimetric improvements when compared to the benchmark data. Particularly the
plans optimised for patients from the third centre, not participating to the training, resulted in superior quality. The
data suggests that the new engine is reliable and could encourage its application to clinical practice.
Keywords: Knowledge based planning, RapidPlan, RapidArc, Esophageal cancer
Background
In the recent past, knowledge-based approaches were
studied and applied to some components of the radio-
therapy chain, in particular to treatment planning. Early
pre-clinical and clinical experiments have been per-
formed [1–7] to demonstrate the feasibility of predicting
appropriate dose-volume constraints starting from ap-
propriate modelling of historical data. The groups of the
Duke University [1–5] and of the Washington University
[6, 7], pioneers in knowledge-based planning, provided
evidence about the improved plan quality, reduced inter-
clinician variability, and about the possibility to transfer
the planning expertise from more experienced centres to
less experienced institutions.
In this frame, a recent commercial implementation of
knowledge-based planning was released by Varian Medical
Systems (Palo Alto, USA), the RapidPlan system. Early
pre-clinical validation studies have been published [8–10]
investigating its role for the planning of liver, prostate and
lung and head and neck cancer, using VMAT and IMRT
technologies. In all these studies, the primary focus was
the appraisal of the quality of the models built from
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relatively limited sets of patients, and the determination
of efficient methods for the model validation. The aim
of the RapidPlan system is to enable the automatic gen-
eration of individualised dose-volume constraints for
any new patient based on the knowledge and the mod-
elling of historical (or library-based) planning data. The
dose-volume constraints obtained from this modelling
should result: i) consistent with the consolidated clin-
ical practice, ii) achievable, i.e. encompassing and solv-
ing possible trade-offs between conflicting clinical
objectives and iii) optimal, in the sense that the overall
solution should represent the best balance between all
requests and the most effective healthy tissue protec-
tion, specific for the new patient. All the above can be
realised in the assumption that the models are built
from libraries of properly selected cases, i.e. cases opti-
mised by experienced planners with the implementa-
tion of state-of-the-art clinical objectives. The use of
this approach might streamline the optimisation
process by minimising the need of interactive or itera-
tive determination of planning objectives and, also, in-
crease the consistency and the transferability of
planning knowledge within and among a network of
institutions.
Volumetric modulated arc therapy (VMAT) has been
investigated for esophageal cancer in a limited number
of planning studies [11–18], and clinical results are still
to be provided. From these investigations, VMAT re-
sulted technically feasible with superior results in terms
of dose distributions (target coverage and organs at risk
(OAR) sparing) compared to 3D conformal therapy and
also to fixed field intensity modulated therapy (IMRT).
The aim of the present study was to demonstrate the
possibility to build, using a commercial system, a pre-
dictive model able to generate dose volume histogram
and constraints for optimizing VMAT plans for esopha-
geal cancer patients. Plan data from the databases of
three institutions were selected for the study. Data from
two clinics, with similar patient recruitment and plan-
ning strategies were used for the model definition and
training. Independent groups of plans from all three
clinics, not used for the training, were then used for the
model validation. The rationale for keeping clinic C in
the validation phase only, is to understand if a model
generated from plans with certain characteristics can be
effectively used in a broad-scope to transfer expertise
from more experienced centres to either less experi-
enced or more peripheral institutions with less resources
and/or excessive workload.
Matherial and methods
A new knowledge-based optimisation engine, named
RapidPlan, was introduced in the Eclipse treatment plan-
ning system (Varian Medical Systems, Palo Alto, USA)
from its release 13.5. First studies on pre-clinical valid-
ation have been recently published [8–10] and details on
its implementation in Eclipse and its main features can
be therein found. A more detailed description of the
mathematical implementation and of the algorithms ap-
plied can be found in [19, 20]. In summary, RapidPlan
has three components: i) a model building and training
environment (DVH Estimation Model Configuration); ii)
an automated model based dose-volume constraints pre-
diction tool (DVH Estimation); iii) a new VMAT and
IMRT optimisation algorithm (PO, Photon Optimizer).
The DVH estimation model configuration
A model uses a set of plan optimisation rules (chosen
objectives and priorities) for structures (target volumes
or OARs) included in the model itself. Objectives and
priorities can be manually and numerically assigned, or
generated for the specific patient by the model. The
model is configured from a number of relevant geomet-
ric and dosimetric features from a set of selected plans.
During the configuration process, a combination of Prin-
cipal Component Analysis and regression techniques
(PCA-regression) is applied for the in-field region of the
OARs, and a mean and standard deviation model for the
other OAR regions. The final result is a set of model pa-
rameters that are used in the next step to estimate the
DVHs for a new case.
Built-in model training evaluation
A statistical summary about the goodness of the model
is produced as an output of the training phase. Some pa-
rameters provide assessment about the model goodness-
of-fit and will be summarised in the results. The DVH’s
and GED’s (Geometry-based Expected Dose) principal
component average fits indicate the percentage of cases
in the training properly reconstructed by the model. The
coefficient of determination of the regression model pa-
rameters and the whole estimation model fit, measure
the variance and the quality of the regression model: a
good fit gives value close to 1. The average chi square of
the regression model parameters (Pearson’s chi-squared
test) represents the difference between the original and
the estimated data: the closer to 1 the better the fit. The
goodness-of-estimation is expressed by the mean squared
error between original and estimate, that measures the
distance between the original DVH and the mean of the
upper and lower bounds of the estimated DVH: the closer
to 0 the better. The percentage of dose bins falling outside
the estimation bounds should be 32 % in the ideal case
(out of 1 SD).
The DVH estimation
This component is used for generating estimated DVH
and optimization objectives for a plan of a new patient.
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From the DVH estimation model parameters, the most
probable, upper and lower bound DVHs are generated
using the PCA-regression model for the OAR in-field re-
gion, and the mean and standard deviation model for
the other OAR regions. Once the upper and lower
bound DVHs are computed, the objective generation
phase determines the dose volume constraints (lines
and/or points, user definable) to use in the optimization
process, according to the choices in the model configur-
ation. Users might also be free to add further objectives,
modify priorities and perform interactive optimisation if
needed.
Model definition and validation
Patients selection: the case of esophageal cancer was se-
lected for this investigation.
Seventy patients, from two clinics, previously planned
with RapidArc VMAT (Varian, Palo Alto, USA) were se-
lected for the training. All plans were approved for clin-
ical use. Forty patients were provided by clinic A with
dose prescriptions ranging from 40 to 60Gy (1.8-2.5 Gy/
fraction); 30 patients were selected from the database of
clinic B and were all planned with a dose prescription of
41.4Gy (1.8Gy/fraction). Patients were select to sample
with equal proportions the three districts for the local-
isation of the PTV (upper, medial and lower third of the
esophagus). No other special criteria were applied for
the selection of training cases except the fact that were
all judged clinically acceptable and usable for treatment.
Additional 40 patients, not used for the model config-
uration and training, were selected for the validation; 15
each from clinics A and B and 10 from a third clinic C
(this was added to better test the generalisation power of
the system). The latter group was characterised by a dif-
ferent strategy in target definition, and a dose prescrip-
tion of 50.4Gy (1.8Gy/fraction). Clinic C is experienced
in the RapidArc technique, but has an extreme workload
and relatively limited resources compared to the others.
Details about the planning strategy of the group C can
be found in [13].
The clinical target volume (CTV) was delineated to in-
clude the gross tumour and nodal disease, as identified
from the endoscopic and the imaging studies. Regional
nodes and the celiac axis were also added to the CTV.
The CTV was created by the expansion of CTV with 20
mm in the craniocaudal and 15 mm in the radial direc-
tions. The planning target volume was obtained with an
uniform expansion of 5mm from the CTV.
DVH estimation model characteristics: the model was
here configured to give line-type objectives for all in-
volved OARs with optimisation priorities generated by
the system. A line-type objective is in theory defined as
a continuous objective line representing the desired
DVH; objectives of this type would maximize the DVH
constraint strength in the whole dose range. In practice,
continuous lines are represented by a discrete number of
dose-volume constraint points and in the Eclipse imple-
mentation these are at least 5 equally spaced over the dose
range of the DVH. The usage of generated priorities
would leave the model to find the best possible solution
for the specific patient and related anatomy; fixed prior-
ities are more for a template-based approach. Constraints
and priorities for the PTV and CTV volumes were manu-
ally set to predefined values [9] to ensure coverage.
The OARs included in the study were: left and right
lungs, heart and spinal cord (spine). For patients with
target in the mid or lower-third of the esophagus, add-
itional OARs were included: liver, spleen, left and right
kidneys, stomach and small bowel. The average PTV
volume was 650 ± 270cm3 (range: 125-1209cm3) for the
training dataset and 397 ± 250cm3 (range: 54-1097cm3)
for the entire validation cases.
The Acuros-XB dose calculation algorithm was
adopted with a dose resolution of 2.5mm. Acuros was
applied as the algorithm for the final dose calculation as
well as for the so-called intermediate dose calculation.
In this study the intermediate dose calculation was auto-
matically run at the end of the optimisation phase to re-
fine the convergence to the planning objectives and it
results particularly effective when air cavities or signifi-
cant tissue heterogeneities, especially with low densities,
are involved. Plans were optimised for 6MV photon
beams for RapidArc with one or two full arcs. All plans
were normalised to the mean dose to PTV. Standard
DVH analysis was performed to appraise the quality of
the model-based optimised plans versus the clinically ac-
cepted baseline benchmark. Normal distribution of data
was assessed and confirmed.
A number of dose-volume objectives were used to ap-
praise the quality of the reference and RapidPlan dose
distributions and were quantitatively analysed for PTV
and OAR. All objectives are listed in detail in the result
tables. As reference, the clinically accepted plans were
selected.
To further appraise the RapidPlan data in comparison
with the reference plans, for each patient, PTV and OAR
and for all dose volume objectives (a total of 564 data
points) a pass-fail analysis was performed. Data were
grouped in 4 classes: class 1 for failed-passed cases
(reference-failed and RapidPlan-passed); class 2 for passed-
failed; class 3 for failed-failed and class 4 for passed-passed.
A test-point is defined as passed if the value in the
plan (either RapidPlan of the reference) improved the
dose-volume objective and failed in the opposite case.
Results
A qualitative and quantitative overview of the output of
the model configuration phase can be found in the
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Additional file 1. Table 1 reports a summary of the model
training statistics. Some structures were present only in
the cases where the PTV was located in the mid and mid-
lower thirds of the esophagus. The quality of the regres-
sion appeared good: more than 99 % of the cases were
reproduced in the DVH or GED (97 % for the left kidney)
components, with an average chi square of 1.08 ± 0.04.
Figure 1 shows, for 20 of the 40 cases (chosen every
second patient, i.e. almost randomly since patients were
not ordered according to any relevant parameter like
tumor volume or localisation) used in the validation
(including all the 10 cases from center C), the prediction
bands generated by the DVH estimation engine as well as
the final DVH lines after full optimisation and calculation
for the left and right lungs. To notice: i) the estimation
bands are narrow, ii) the final DVH falls normally below
the lower limit of the bands (according to the generated
line objective). Both observations support the good predic-
tion power of the model.
Figure 2 shows the dose distributions (the colorwash is
in the range 20–110 %) for one case from clinic C. The
comparison is between the reference plan (left panels)
and the RapidPlan data (right panels). Figure 3 reports
the average DVHs for CTV, PTV and OAR comparing
the reference and the RapidPlan data for clinic C
(Additional file 1: Figures S4 and S5 show the same for
the clinics A and B). RapidPlan allowed to modestly im-
prove some of the OARs (e.g. heart) with some more re-
markable effect on the spleen.
Table 2 presents the summary of the quantitative ana-
lysis of the DVH for the entire group of 40 patients in
the validation; p values are reported only when signifi-
cant (<0.05) or when a tendency to significance (p < 0.1)
was observed. The data confirm that modest but system-
atic improvements can be achieved with RapidPlan.
Table 3 presents the same summary but limited to the
10 cases from clinic C. The data resulted consistent with
the general analysis despite the different strategies in tar-
get definition and OARs contouring, the variations in
tumour stages, and in the dose prescriptions. On aver-
age, planning objectives were met for both the entire co-
hort as well as for the clinic C dataset.
Finally, Table 4 presents the results of the case-by-case
pass-fail analysis conducted on all the 40 validation pa-
tients and for all the planning objectives. Of the 624
dose-volume test points, 21 (3.3 %) were scored as fail-
ure for the reference plans and pass for the RapidPlan.
Of these, 14 were from the clinic C dataset. Only 3
points (<0.5 %) resulted with RapidPlan failing when the
reference plan succeeded (none from group C). Overall,
RapidPlan resulted equivalent or superior to the refer-
ence plans in almost the totality of the cases.
Table 1 Summary the model training statistics
Lung left Lung right Heart Spine Liver
Structures in model 70 70 70 70 65
Estimation model goodness of fit
DVH average fit 0.99 0.99 0.99 0.99 0.99
GED average fit 0.99 0.99 0.99 0.99 0.99
Coeff. of determination 0.83 0.92 0.73 0.49 0.88
Whole estimation model fit 0.83 0.91 0.73 0.49 0.87
Average chi square 1.07 1.09 1.04 1.05 1.05
Model goodness of estimation
MSE original and estimate 0.001 0.001 0.005 0.01 0.002
Dose bins outside bound.[%] 41 42 35 28 41
Spleen Stomach Left kidney Right kidney Small bowel
Structures in model 60 64 34 31 40
Estimation model goodness of fit
DVH average fit 0.99 0.99 0.99 0.99 0.99
GED average fit 0.99 0.99 0.97 0.99 0.99
Coeff. of determination 0.88 0.95 0.79 0.84 0.95
Whole estimation model fit 0.87 0.95 0.76 0.82 0.94
Average chi square 1.02 1.09 1.08 1.11 1.15
Model goodness of estimation
MSE original and estimate 25 0.002 0.01 0.004 0.003
Dose bins outside bound.[%] 0.005 39 29 23 44
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Planning time was not part of the study design since
its evaluation is prone to a number of subjective or ex-
ternal factors not easy to objectively quantify. In particu-
lar, the experience of individual planners and workload
as well as computer hardware have a strong influence.
Limiting to the RapidPlan aspects, some data were col-
lected. Once plans are identified as good candidates for
the model training, the time needed to “extract” the data
and load them into the configuration workspace is lim-
ited to about 15–20 s per plan. The time needed to train
a model is approximately 2 min. Being an investigational
study, the time needed to validate a model prior to the
dosimetric experiments, cannot be assessed and will be-
come clearer when the learning phase will be completed.
Plan optimisation with the DVH estimation engine re-
quires about 15–20 s for the constraints generation and,
in the case of esophagus, about 10–15 min of free-run
optimisation inclusiding of the so-called intermediate
dose calculation phase. The time needed for final dose
calculation is independent from the knowledge-based or
conventional approach applied for optimisation and de-
pends on the algorithm and the case complexity. For
esophageal cancer it takes about 6–8 min to perform a
full dose calculation with Acuros-XB.
Discussion
The scope of the present study was to appraise the pos-
sibility to use a knowledge-based dose-constraint predic-
tion engine for plan optimisation of VMAT with
clinically acceptable results. Previous studies [8–10]
demonstrated the possibility of developing and using
models for liver, lung, prostate and head and neck can-
cer patients. Validation tests showed that plan quality
was not inferior, while in some instances superior when
knowledge-based methods were applied to generate the
optimisation dose-volume constraints compared to the
routine clinical practice. All the published validation experi-
ments of RapidPlan were performed using only cases
pooled from the databases of the same institutions provid-
ing the model training cases. The approach of RapidPlan is
Fig. 1 Examples of estimated DVH ranges (solid bands) and final DVH after optimisation with the model-based algorithm. Data are shown for left
and right lungs for 20 of the 40 patients (chosen every second patient) used for the validation. Similar patterns for the other patients and organs
at risk
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based on the automated prediction of individualized dose-
volume objectives from a population-based or library-based
historical knowledge. This differs from other possible ap-
proaches that are currently available in clinical routine as
class solutions or fixed templates or that have been pre-
sented and are investigated like the use of or selection from
pools of Pareto-optimal groups of plans. The use of class
solutions and templates, although simple to implement, has
the limit given by the static nature of those objects. Any in-
dividualisation of the objectives is prone to the need of
trial-and-error planning and might lead to sub-optimal
planning when challenging patients or un-experienced
Reference RapidPlan
Fig. 2 Example dose distributions for the reference plan and for the model-based optimised plan for the clinic C. The colour-wash is from 20 %
to 110 % of the prescription dose (50.4Gy)
Fig. 3 Average DVH for target volumes and organs at risk for the validation experiment for the clinic C. The Reference lines are for the original
plans manually optimised, while the RapidPlan lines are for the model-based optimisation
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planners are involved. The other type of approach is more
interesting and in principle, following different paths, and
should aim to the same results: an individualised determin-
ation of the best plan from the optimisation of the trade-
offs between competing objectives. Several studies [21–26]
investigated the role of multi-criteria optimization (a form
of Pareto-optimal navigation approach) for both IMRT and
VMAT and demonstrated the possibility to maximise the
sparing of organs at risk with preservation of target cover-
age. The difference between the RapidPlan and the Pareto-
optimal approaches is mostly in the methodology: the first
aims to determine automatically the best personalized con-
straints, given the prescription requirements, the clinical
objectives and the historical knowledge; the latter starts
from static clinical objectives and navigates through the
realm of possible solutions to find the optimal plan. The de-
gree of automation of the process can be different between
the two approaches and dedicated comparative studies
would be needed to ascertain if one approach might be
preferable. At the present status this evidence is missing
and both methods appear to be very promising.
It is not directly relevant for the scope of these investi-
gations to discriminate if the use of physical or biological
(like EUD or NTCP) constraints are used to generate the
ideal optimisation results. Incidentally, within RapidPlan,
but not investigated here, it is possible to design the model
with any combination of physical dose-volume constraints
and/or generalised EUD for targets and OARs.
Table 2 Summary the DVH analysis for the reference and the
RapidPlan plans for the entire cohort of validation patients from
the 3 clinics
Objective Reference RapidPlan p
PTV
Mean [%] 100 % 100.0 ± 0.0 100.0 ± 0.0 -
D1% [%] <107 % 104.2 ± 3.2 103.8 ± 3.1 -
V95% [%] >95 % 97.3 ± 2.9 98.0 ± 1.2 -
St. Dev. [%] <5 % 2.1 ± 0.1 2.0 ± 0.1 -
Left lung
Mean [Gy] <15Gy 8.9 ± 4.2 9.1 ± 4.8 -
V20Gy [%] <20% 12.4 ± 10.2 12.6 ± 11.0 -
Right lung
Mean [Gy] <15Gy 9.2 ± 4.8 9.1 ± 5.2 -
V20Gy [%] <20 % 12.1 ± 11.3 12.2 ± 11.7 -
Heart
Mean [Gy] <25Gy 11.9 ± 9.9 10.7 ± 8.3 0.03
V30Gy [%] <30 % 10.3 ± 16.1 7.0 ± 8.9 0.07
Spine
D1cm3 [Gy] <45Gy 26.2 ± 11.5 23.6 ± 9.7 0.001
Liver
Mean <15Gy 8.5 ± 5.9 8.6 ± 6.4 -
Spleen
Mean [Gy] <20Gy 14.3 ± 7.6 12.3 ± 6.3 0.004
D1% [Gy] <40Gy 32.6 ± 10.6 30.6 ± 11.0 -
Left kidney
V15Gy [%] <35 % 16.4 ± 16.9 12.7 ± 18.7 0.03
Right kidney
V15Gy [%] <35 % 4.7 ± 7.3 3.4 ± 5.0 -
Stomach
D1% [Gy] <50Gy 43.3 ± 8.8 42.5 ± 9.9 0.07
Small bowel
Mean [Gy] <10Gy 6.6 ± 3.1 6.3 ± 3.0 0.03
D1% [Gy] <45Gy 25.6 ± 9.2 24.6 ± 8.6 -
Table 3 Summary the DVH analysis for the reference and the
RapidPlan plans for the cohort of validation patients from the
clinic C
Objective Reference RapidPlan p
PTV
Mean [%] 100 % 100.0 ± 0.0 100.0 ± 0.0 -
D1% [%] <107 % 105.0 ± 1.0 104.8 ± 0.9 -
V95% [%] >95 % 96.5 ± 2.5 97.1 ± 1.1 -
St. Dev. [Gy] <5 % 2.5 ± 0.8 2.4 ± 0.8 -
Left lung
Mean [Gy] <15Gy 11.4 ± 4.7 10.6 ± 4.2 0.01
V20Gy [%] <20 % 22.4 ± 10.6 18.9 ± 7.2 0.01
Right lung
Mean [Gy] <15Gy 12.6 ± 5.5 11.9 ± 5.3 0.01
V20Gy [%] <20 % 24.4 ± 12.3 21.7 ± 11.2 -
Heart
Mean [Gy] Minimise 15.4 ± 15.1 11.9 ± 11.9 0.06
V30Gy [%] <30 % 22.7 ± 25.5 16.2 ± 18.7 0.02
Spine
D1cm3 [Gy] <45Gy 43.3 ± 3.8 43.1 ± 4.4 0.01
Liver
Mean Minimise 4.9 ± 7.1 4.5 ± 6.4 0.01
Spleen
Mean [Gy] Minimise 19.7 ± 4.2 13.9 ± 3.5 -
D1% [Gy] Minimise 45.5 ± 3.2 43.8 ± 4.1 -
Left kidney
V15Gy [%] <35 % 14.0 ± 16.5 11.5 ± 14.3 -
Right kidney
V15Gy [%] <35 % 3.8 ± 4.6 3.7 ± 4.9 -
Stomach
D1% [Gy] Minimise 60.8 ± 0.6 61.5 ± 0.1 -
Small bowel
Mean [Gy] Minimise 7.7 ± 2.4 6.7 ± 2.3 0.01
D1% [Gy] <45Gy 39.3 ± 7.0 38.8 ± 6.9 -
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Other automated objective definition methods were
studied. Multi-criteria plan optimisation based on a set of
“wish-list” prescription objectives, together with the selec-
tion of beam geometries from libraries of candidate direc-
tions enabled the development of sets of Pareto-optimal
IMRT plans. In 97 % of the cases tested in a prospective
clinical study for head and neck cancer, the automatically
generated plans resulted preferable [27, 28].
Among these, methods to automatically adjust the objec-
tives during optimisation (autoplan concept) enabled some
degree of automation [29, 30]. Also data-driven methods
were developed in research-based planning systems. The
investigation of the spatial relationships between OARs and
targets and the automatic generation of objectives derived
from a database of cases and used as initial planning goals
was demonstrated to be reliable and suggestive of possible
automation of IMRT planning [31–33].
Knowledge-based planning methods (or Pareto-
optimal multi-criteria methods) do not eliminate the
need to perform individual plan optimisation and cal-
culation. The scope of these approaches is to automate
and individualise at maximum the process of optimisa-
tion with the definition of the best constraints possibly
minimizing interactive and iterative interventions. The
actual optimisation and final calculation can already
today be made automatic by the existing commercial
implementations so, with the demonstration of the reli-
ability of knowledge based methods, a further step to-
wards complete automation of the inverse planning
process is achieved.
Table 4 Summary of the case-by-case pass-fail analysis for the selected dose-volume planning objectives for the reference and for
the model-based plans for all the validation cases
Objective Reference fail Reference pass Reference fail Reference pass
Rapidplan pass RapidPlan fail RapidPlan fail RapidPlan pass
PTV (40 cases)
D1% [%] <107 % 0 (0 %) 0 (0 %) 0 (0 %) 40 (100 %)
V95% [%] >95 % 5 (12 %) 0 (0 %) 0 (0 %) 35 (88 %)
St. Dev. [%] <5 % 0 (0 %) 0 (0 %) 0 (0 %) 40 (100 %)
Left lung (40 cases)
Mean [Gy] <15Gy 1 (2 %) 0 (0 %) 4 (10 %) 35 (90 %)
V20Gy [%] <20 % 1 (2 %) 0 (0 %) 5 (12 %) 34 (86 %)
Right lung (40 cases)
Mean [Gy] <15Gy 0 (0 %) 2 (5 %) 2 (5 %) 36 (90 %)
V20Gy [%] <20 % 2 (5 %) 0 (0 %) 5 (12 %) 33 (83 %)
Heart (40 cases)
Mean [Gy] <25Gy 2 (5 %) 0 (0 %) 2 (5 %) 36 (90 %)
V30Gy [%] <30 % 2 (5 %) 0 (0 %) 1 (2 %) 37 (94 %)
Spine (40 cases)
D1cm3 [Gy] <45Gy 3 (7 %) 0 (0 %) 1 (2 %) 36 (91 %)
Liver (31 cases)
Mean <15Gy 1 (3 %) 1 (3 %) 3 (10 %) 26 (84 %)
Spleen (25 cases)
Mean [Gy] <20Gy 1 (4 %) 0 (0 %) 1 (4 %) 23 (92 %)
D1% [Gy] <40Gy 1 (4 %) 0 (0 %) 5 (20 %) 19 (76 %)
Left kidney (16 cases)
V15Gy [%] <35 % 0 (0 %) 0 (0 %) 1 (6 %) 15 (94 %)
Right kidney (16 cases)
V15Gy [%] <35 % 2 (12 %) 0 (0 %) 0 (0 %) 14 (88 %)
Stomach (31 cases)
D1% [Gy] <50Gy 0 (0 %) 0 (0 %) 2 (6 %) 29 (94 %)
Small bowel (20 cases)
Mean [Gy] <10Gy 0 (0 %) 0 (0 %) 1 (5 %) 19 (95 %)
D1% [Gy] <45Gy 0 (0 %) 0 (0 %) 0 (0 %) 20 (100 %)
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It is of course true that the findings presented in this
study are depending upon the specific software solution
implemented by the vendor and are directly applicable
only to centres having similar infrastructures. Neverthe-
less, the role of knowledge-based optimisation engines
and the clinical usability of these methods has a more
general value and might give insights to future directions
of developments of the radiotherapy chain.
In the present study, the case of esophageal cancer
was chosen to investigate the performance of a broad-
scope knowledge-based model. The concept of broad-
scope was realised with, on one side, the selection of a
heterogeneous set of plans for the training (wide range
of dose prescriptions, huge variation in target size and
localisation from the upper to the lower third - with par-
tial inclusion of the stomach -) to predict patient tailored
dose-volume objectives for inverse planning. The rele-
vant variation in dose prescription was due to the differ-
ent localisation of the target, the various trade-off with
OARs, and the different protocols applied. The variation
in target size and shape (from short-symmetric targets in
the upper third to very elongated-symmetrical in the cen-
tral and central-lower to the elongated and asymmetric-
lateral targets of the lower third) added complexity to the
optimisation process. The presence of many OARs, with
very different sizes and geometrical relationships to the
target induced several trade-off problems and challenged
the achievement of the planning objectives. The sub-
analysis on two groups with symmetric or asymmetric tar-
gets did not lead to any significant difference compared to
the main results. This was expected since the model was
trained with a cohort of mixed cases with equivalent inci-
dence of both classes. The DVH estimation engine dem-
onstrated a sufficient generalisation power and generated
adequate predictions for both groups during the valid-
ation. Similarly no difference was found in diviging the
group of patients by upper, medium or lower third of the
esophagus for the same reason. A training set which sam-
ples the patient population with an adequate case mix can
be used for a general purpose. .
As a second side of the broad-scope investigation, the
model validation was performed on three groups of
cases (not used for the training). Two sets of cases from
each of the two clinics contributing to the training and
one set from a third, external, clinic. This was similar to
the concept investigated by Good et al. in their study
[5]. Only if the model-based approach gives results
equivalent or superior to the corresponding reference
plans optimised with traditional methods in the external
clinic, the validity of the model and its broad-scope are
proven. The here presented results demonstrated that
this was indeed the case, and the model, built with 70
patients from clinics A and B resulted adequate to prop-
erly optimise plans from clinic C. The actual exchange
of the model between centers would be quite easy since
all the necessary data (the parameters fit from the train-
ing phases) can be exported in binary encrypted format
from one center and simply reimported into the Eclipse
planning system of the destination center. No exchange
of any patient data would be necessary for the purpose.
From an operational perspective, the RapidPlan
knowledge-based engine allowed to generate and train a
predictive model of clinically acceptable performance. The
number of cases used for training was 70, greater than
what used in the liver or lung and prostate experiments
(27 or 45) or in the head and neck study (30 or 60), but
still reasonably limited to allow patient selection in a
medium sized clinic. The training set was determined
without special selection criteria. The guideline followed
for the study was to include in the training set an adequate
representation of the population to be sampled. In the
present case, three main subgroups were identified ac-
cording to the location of the tumor and the number of
training cases used scaled with the number of classes
times the minimum number of patents per OAR to build
a model (which is 20). The results obtained thus reinforce
the possibility to build effective broad-scope models and,
likely, suggest that, to some extent, the use of heteroge-
neous datasets (in their geometric and dosimetric aspects)
might be useful if not necessary. Further studies are
needed to determine the correlation between heterogen-
eity of the input data, number of training cases needed,
and generalisation power of the models. The present re-
sults suggest that modest numbers are sufficient to repre-
sent wide clinical conditions.
The detailed analysis of the residual planning criteria
violations, showed that the knowledge-based plans pre-
sented fewer failures than the original clinical plans but
still not all criteria were met for all patients (the 3 cases
of class 2 pass-fail findings). The present results are gen-
erated with no user interaction during the optimisation
runs, and therefore might suggest some challenge when
complex trade-offs are present. In such cases it would be
possible to apply manual interactive refinements during
the optimisation.
The validation based on patients originated from a de-
partment not member of the training group, as in the
present study, is the proof of the broad-scope model con-
cept value. The fact that with RapidPlan it was possible to
generate plans systematically equivalent or superior to the
reference also for this centre, demonstrates a good power
of generalisation. As a consequence, the transfer of the
planning knowledge from more experienced and profiled
centres to either less advanced or more busy institutions
is shown to be possible. It would possibly be conceivable
the use of properly built broad-scope models to harmonise
and uniform the planning phases for multicentric trials
(provided compatible systems are available).
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Conclusions
RapidPlan, a novel knowledge-based DVH estimation
model was successfully configured, trained and validated
for esophageal cancer. The system allowed to improve
the quality of VMAT RapidArc plans against the refer-
ence clinically accepted plans. In particular RapidPlan
based plans resulted superior to reference plans for the
cases provided by a clinical centre not having contrib-
uted to any case in the model training phase. Results are
suggestive for a reliable application of the methodology
to the clinical routine.
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